Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16106743 | 1.00 | NR1I2 (0.39) | NR1I2POLBSPHK1SCN3AMAOA | |
| SCHEMBL3276055 | 0.89 | POLB (0.40) | NR1I2POLBSPHK1SCN3AMAOA | |
| SCHEMBL5216730 | 0.89 | POLB (0.40) | NR1I2POLBSPHK1SCN3AMAOA | |
| SCHEMBL16106745 | 0.86 | HTT (0.40) | NR1I2POLBSPHK1SCN3AMAOA | |
| SCHEMBL1466682 | 0.86 | HTT (0.40) | NR1I2POLBSPHK1SCN3AMAOA | |
| SCHEMBL1466679 | 0.86 | HTT (0.40) | NR1I2POLBSPHK1SCN3AMAOA | |
| SCHEMBL15664773 | 0.84 | NR1I2 (0.53) | NR1I2POLBSPHK1LMNABCHE | |
| SCHEMBL7278054 | 0.84 | NR1I2 (0.53) | NR1I2POLBSPHK1LMNABCHE | |
| SCHEMBL1360593 | 0.84 | CYP1A2 (0.40) | NR1I2LMNASMN1; SMN2 | |
| SCHEMBL2563563 | 0.84 | LMNA (0.38) | POLBSPHK1SCN3AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | claimed |
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA PHARMA S.A. (FR) | 2005-10-27 | — | — | US | disclosed |
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED | 2004-12-02 | — | — | US | disclosed |
| US-6673803-B2 | FOR TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS; ACTIVITY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | ZENECA LIMITED (GB) | 2004-01-06 | — | — | US | disclosed |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | disclosed |
| EP-0929530-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | disclosed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, FLT1, NR5A1 | NR1I2 81/4885POLB 2602/4885SPHK1 3263/4885 |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, FLT1, VEGFA | NR1I2 119/4885POLB 2629/4885SPHK1 3395/4885 |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NR5A1, NR5A2, CNKSR1 | NR1I2 11/4885POLB 3303/4885SPHK1 2298/4885 |
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | NR5A1, NR5A2, CNKSR1 | NR1I2 11/4885POLB 3303/4885SPHK1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.